ATE469158T1 - Heteroalkylgebundene pyrimidinderivate - Google Patents

Heteroalkylgebundene pyrimidinderivate

Info

Publication number
ATE469158T1
ATE469158T1 AT06813133T AT06813133T ATE469158T1 AT E469158 T1 ATE469158 T1 AT E469158T1 AT 06813133 T AT06813133 T AT 06813133T AT 06813133 T AT06813133 T AT 06813133T AT E469158 T1 ATE469158 T1 AT E469158T1
Authority
AT
Austria
Prior art keywords
compounds
heteroalkyl
pyrimidine derivatives
bonded
useful
Prior art date
Application number
AT06813133T
Other languages
English (en)
Inventor
Stephanie Blanchard
Kantharaj Ethirajulu
Cheng Hsia Lee
Harish Nagaraj
Ander Poulsen
Eric Sun
Yee Ling Tan
Ee Ling Teo
Anthony William
Original Assignee
S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by S filed Critical S
Application granted granted Critical
Publication of ATE469158T1 publication Critical patent/ATE469158T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT06813133T 2005-11-16 2006-11-15 Heteroalkylgebundene pyrimidinderivate ATE469158T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73683805P 2005-11-16 2005-11-16
US81733906P 2006-06-30 2006-06-30
US85128306P 2006-10-13 2006-10-13
PCT/SG2006/000353 WO2007058628A1 (en) 2005-11-16 2006-11-15 Heteroalkyl linked pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE469158T1 true ATE469158T1 (de) 2010-06-15

Family

ID=38048928

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06813133T ATE469158T1 (de) 2005-11-16 2006-11-15 Heteroalkylgebundene pyrimidinderivate

Country Status (20)

Country Link
US (5) US8143255B2 (de)
EP (1) EP1951729B1 (de)
JP (2) JP5380073B2 (de)
KR (5) KR101576159B1 (de)
CN (2) CN101365703B (de)
AT (1) ATE469158T1 (de)
AU (2) AU2006316071B2 (de)
BR (1) BRPI0618552B8 (de)
CA (2) CA2629443C (de)
CY (1) CY1116156T1 (de)
DE (1) DE602006014579D1 (de)
DK (2) DK1951730T3 (de)
ES (2) ES2506040T3 (de)
MY (1) MY148072A (de)
NZ (1) NZ568325A (de)
PH (1) PH12012501003B1 (de)
PL (1) PL1951729T3 (de)
PT (2) PT1951730E (de)
TW (3) TWI525096B (de)
WO (2) WO2007058627A1 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1697384B1 (de) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NZ567851A (en) 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US10517876B2 (en) * 2005-11-16 2019-12-31 Cti Biopharma Corp. Oxygen linked pyrimidine derivatives
AR061185A1 (es) 2006-05-26 2008-08-13 Chugai Pharmaceutical Co Ltd Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
EP2044084B1 (de) 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki-derivate des chinazolins
RU2009136343A (ru) * 2007-03-01 2011-04-10 Чугаи Сейяку Кабусики Кайся (Jp) Макроциклическое соединение
WO2008140420A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyrimidine derivatives
WO2008140419A2 (en) * 2007-05-15 2008-11-20 S*Bio Pte Ltd Pyridyl substituted pyrimidine derivatives
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2283024B1 (de) 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilinopyrimidine als plk-kinase-inhibitoren
US8871753B2 (en) 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
EP2376499B1 (de) * 2008-12-11 2015-02-25 Cti Biopharma Corp. 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-dekaene zitrat- salz
WO2010068182A1 (en) * 2008-12-11 2010-06-17 S*Bio Pte Ltd 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
MX2012000680A (es) * 2009-07-15 2012-02-28 S Bio Pte Ltd Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)-7,12,25-trioxa-1 9,21,24-triaza-tetraciclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2 ,4,9,14,16,18(26),20,22-nonaeno.
ES2632548T3 (es) * 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN102127087B (zh) * 2011-01-21 2012-07-04 江苏先声药物研究有限公司 喹唑啉衍生物
CN102757448B (zh) * 2011-04-26 2016-04-06 中南大学 大环类激酶抑制剂化合物、制备方法及其作为药物的应用
MX342177B (es) * 2011-09-30 2016-09-20 Ipsen Pharma Sas Inhibidores de cinasa 2 de repeticion rica en leucina (lrrk2) macrociclica.
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
CN102617599B (zh) * 2012-04-10 2014-04-16 江苏先声药物研究有限公司 大环类化合物及其应用
CA2904148A1 (en) * 2013-03-14 2014-10-02 Concert Pharmaceuticals, Inc. Deuterated pacritinib
CN105164136B (zh) * 2013-05-06 2017-12-22 默克专利股份公司 作为激酶抑制剂的大环化合物
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
AR101504A1 (es) 2014-08-11 2016-12-21 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6
EP3179991B1 (de) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutische kombinationen eines btk-inhibitors und eines bcl-2-inhibitors
FR3025200B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
FR3025199B1 (fr) * 2014-09-02 2016-09-23 Pf Medicament Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
BR112017005299A2 (pt) 2014-09-17 2017-12-12 Ipsen Pharma Sas inibidores de lrrk2 cinase macrocíclicos
EP3206749B1 (de) 2014-10-14 2021-09-08 The Regents of the University of California Die cdk9- und brd4-hemmern flavopiridol und jq1 zur hemmung von knorpelentzündungen
WO2016149031A1 (en) * 2015-03-18 2016-09-22 Newave Pharmaceutical Llc Covalent inhibitors of cdk-7
CN105017282B (zh) * 2015-08-28 2017-11-07 苏州明锐医药科技有限公司 帕克替尼的制备方法
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法
US20180318306A1 (en) * 2015-09-28 2018-11-08 Cti Biopharma Corp. Methods of treating transplant rejection
CN108368129B (zh) * 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
ES2941687T3 (es) 2016-03-24 2023-05-24 Cothera Bioscience Inc Tratamiento del cáncer con TG02
WO2017196261A1 (en) * 2016-05-11 2017-11-16 National University Of Singapore Jak and hdac dual-inhibitor compounds
KR102758037B1 (ko) * 2017-08-18 2025-01-22 코테라 바이오사이언스 인코포레이티드 Tg02의 다형성 형태
WO2019079357A1 (en) * 2017-10-17 2019-04-25 Silverback Therapeutics, Inc. Tnik modulators, conjugates, and uses thereof
CN108864145B (zh) * 2018-09-14 2021-03-30 兆科（广州）肿瘤药物有限公司 一种氧联嘧啶衍生物的纯化方法
EP3860655A4 (de) * 2018-10-01 2022-08-03 CTI Biopharma Corp. Verfahren zur behandlung von flt3-mutiertem blutkrebs
WO2020097400A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) * 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
US12415816B2 (en) 2018-11-07 2025-09-16 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN111269245B (zh) * 2018-12-04 2021-08-27 杭州百新生物医药科技有限公司 一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
WO2020125513A1 (zh) * 2018-12-19 2020-06-25 凯复制药有限公司 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
EP3958854B1 (de) * 2019-04-22 2025-06-04 University of Pittsburgh - of The Commonwealth System of Higher Education Tg02 zur verwendung in der behandlung von gliomen bei pädiatrischen patienten
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
US12202893B2 (en) 2019-10-04 2025-01-21 Tae Life Sciences, Llc Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereof
CN113583020B (zh) * 2020-04-30 2022-04-22 百极弘烨（广东）医药科技有限公司 一种jak2抑制剂及应用
CN113735879B (zh) * 2020-05-27 2022-05-17 百极弘烨（广东）医药科技有限公司 一种大环jak抑制剂及其应用
WO2022056092A1 (en) * 2020-09-11 2022-03-17 Cti Biopharma Corp. Methods of treating viral infection
CN115490705B (zh) * 2021-06-18 2025-04-01 成都凡诺西生物医药科技有限公司 N-大环酰胺类化合物、其制备方法及其作为药物的应用
CN113603708B (zh) * 2021-07-27 2023-08-11 中国药科大学 一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114409674B (zh) * 2022-01-28 2023-07-25 山东大学 一种JAK抑制剂Pacritinib的合成方法
CN117964628A (zh) * 2022-10-24 2024-05-03 科辉智药生物科技(深圳)有限公司 作为cdk9抑制剂的大环类化合物及其应用
CN117447407B (zh) * 2023-12-19 2024-06-11 潍坊医学院 一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
BR9810488A (pt) 1997-06-27 2000-09-12 Ciba Sc Holding Ag Novos catalisadores.
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004039809A1 (ja) * 2002-10-29 2004-05-13 Banyu Pharmaceutical Co., Ltd. 新規キノキサリノン誘導体
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
US20050096324A1 (en) * 2003-11-05 2005-05-05 Zhi-Fu Tao Macrocyclic kinase inhibitors
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
ES2335216T3 (es) * 2003-12-18 2010-03-23 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolina con actividad antiproliferativa.
EP1697384B1 (de) * 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- und pyrimidopyrimidinderivate als anti-proliferative mittel
MY169441A (en) * 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
US9047780B2 (en) * 2012-11-16 2015-06-02 Robert Bosch Gmbh Collision mitigation systems and methods using driver attentiveness

Also Published As

Publication number Publication date
HK1123282A1 (en) 2009-06-12
KR101513492B1 (ko) 2015-04-20
KR20140037256A (ko) 2014-03-26
DK1951730T3 (da) 2010-09-27
DK1951729T3 (da) 2014-10-06
EP1951729A1 (de) 2008-08-06
TW201418263A (zh) 2014-05-16
KR20080086443A (ko) 2008-09-25
AU2006316071A1 (en) 2007-05-24
BRPI0618552A2 (pt) 2011-09-06
JP2009515954A (ja) 2009-04-16
HK1124040A1 (en) 2009-07-03
PT1951729E (pt) 2014-10-02
WO2007058628A1 (en) 2007-05-24
DE602006014579D1 (de) 2010-07-08
CA2629443C (en) 2016-12-13
CN101365703B (zh) 2013-11-06
TW200738735A (en) 2007-10-16
MY148072A (en) 2013-02-28
JP5380073B2 (ja) 2014-01-08
AU2006316071B2 (en) 2011-02-17
CA2629455A1 (en) 2007-05-24
ES2346791T3 (es) 2010-10-20
KR101576159B1 (ko) 2015-12-09
BRPI0618552B1 (pt) 2021-04-06
BRPI0618552B8 (pt) 2021-05-25
CN101360751B (zh) 2011-09-14
TWI407961B (zh) 2013-09-11
ES2506040T3 (es) 2014-10-13
TWI525096B (zh) 2016-03-11
WO2007058627A1 (en) 2007-05-24
PH12012501003B1 (en) 2018-04-06
US20090075999A1 (en) 2009-03-19
CN101360751A (zh) 2009-02-04
EP1951729B1 (de) 2014-06-25
US9573964B2 (en) 2017-02-21
US8143255B2 (en) 2012-03-27
US20090258886A1 (en) 2009-10-15
KR20080090390A (ko) 2008-10-08
KR20140037257A (ko) 2014-03-26
JP5225856B2 (ja) 2013-07-03
KR20140117679A (ko) 2014-10-07
US20120196855A1 (en) 2012-08-02
US20130172338A1 (en) 2013-07-04
CN101365703A (zh) 2009-02-11
AU2006316072B2 (en) 2011-12-22
NZ568325A (en) 2011-05-27
PT1951730E (pt) 2010-08-27
TWI506029B (zh) 2015-11-01
JP2009517344A (ja) 2009-04-30
TW200736262A (en) 2007-10-01
CA2629443A1 (en) 2007-05-24
US20120142680A1 (en) 2012-06-07
PL1951729T3 (pl) 2015-02-27
KR101499594B1 (ko) 2015-03-09
CA2629455C (en) 2017-01-03
US9133214B2 (en) 2015-09-15
US8153632B2 (en) 2012-04-10
PH12012501003A1 (en) 2012-10-29
US8415338B2 (en) 2013-04-09
CY1116156T1 (el) 2017-02-08
AU2006316072A1 (en) 2007-05-24
EP1951729A4 (de) 2009-09-23
KR101568801B1 (ko) 2015-11-12

Similar Documents

Publication Publication Date Title
ATE469158T1 (de) Heteroalkylgebundene pyrimidinderivate
MY150993A (en) Pyrimidine substituted purine derivatives
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
MX2009009537A (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
TW200738659A (en) Novel compounds
TW200724537A (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
TW200800993A (en) Organic compounds
TW200745081A (en) Compounds
SE0300457D0 (sv) Novel compounds
WO2008140420A3 (en) Pyrimidine derivatives
EP2124554A4 (de) Zusammensetzungen und verfahren für die krebsbehandlung
MX2009011576A (es) Nuevos derivados de 4,8-difenil-poliazanaftaleno.
WO2008140419A3 (en) Pyridyl substituted pyrimidine derivatives
WO2008140421A3 (en) Heterocycloalkyl substituted pyrimidine derivatives
PL1732902T3 (pl) Pochodne nukleozydów i ich terapeutyczne zastosowanie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951730

Country of ref document: EP